Faeth Therapeutics Appoints Zymeworks R&D Executive to Board
Faeth Therapeutics appointed Adam Schayowitz, Ph.D., MBA, EVP and Head of R&D at Zymeworks, to its Board of Directors.
Related stories
Dow Jones unofficially closes down 579.15 points, or 1.11%, at 51,763.41
M impact | EQUITY | Oct 30, 2026, 08:00 PM UTC
CorMedix Shares Hit 52-Week Low After DaVita Flags 2027 Reimbursement Drop
CorMedix shares fell nearly 26% on Friday, hitting a fresh 52-week low after DaVita warned that Medicare reimbursement for DefenCath could drop sharply in 2027.
M impact | EQUITY | Oct 30, 2026, 07:51 PM UTC
Broadcom Shares Fall 5.24% to $326.91
Broadcom shares fell 5.24% to $326.91 at 11:25 a.m. ET on October 30.
M impact | EQUITY | Oct 30, 2026, 07:41 PM UTC
SK Hynix Shares Fall 7.08% on October 30
SK Hynix shares closed down 7.08% on October 30. The company outlined a shareholder payout alongside its earnings announcement.
M impact | EQUITY | Oct 30, 2026, 07:41 PM UTC
Amazon Arranges Up to $80 Billion Supplier Financing Credit Line
Amazon arranged a supplier financing credit line of up to $80 billion as it prepares for infrastructure spending on AI initiatives.
H impact | EQUITY | Oct 30, 2026, 07:37 PM UTC
Twilio Shares Fall 17.26% Despite Nearly 24% Free-Cash-Flow Margin
Twilio fell 17.25% to $200.16 on October 30. Its growth outlook overshadowed strong cash generation, the report says.
M impact | EQUITY | Oct 30, 2026, 07:32 PM UTC